Biogen Inc. and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen's immunology ...
Every day, your immune system performs a delicate balancing act, attacking harmful invaders while protecting your own tissues ...